证券代码：002589 证券简称：瑞康医药 公告编号：2023-036 瑞康医药集团股份有限公司 关于聘任董事会秘书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司(以下简称"公司")于 2023 年 8 月 29 日召开公司 第五届董事会第三次会议，审议通过了《关于聘任公司董事会秘书、副总裁的议 案》，董事会同意聘任李喆先生担任公司董事会秘书、副总裁，任职期限自董事 会审议通过之日起至本届董事会届满。李喆先生已取得深圳证券交易所颁发的 《董事会秘书资格证书》，其任职资格符合《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等有关规 定。 一、简历及基本情况 李喆先生：1986 年出生，中国国籍，无境外永久居留权，硕士研究生学历。 历任加拿大永明金融蒙特利尔分部理财顾问、加拿大帝国商业银行多伦多分部基 金管理专员、国金证券上海承销保荐分公司投行项目经理，现任本公司资金管理 部总经理、董事。 截至本公告披露日，李喆先生未直接持有公司股份；与持有公司 5%以上股 份的股东、公司实际 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2023-042 瑞康医药集团股份有限公司 关于累计诉讼情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 截至本公告披露日，公司及控股子公司不存在其他应披露而未披露的重大诉 讼、仲裁事项。 瑞康医药集团股份有限公司（以下简称"瑞康医药"、"公司"）根据《深圳证 券交易所股票上市规则》等有关规定，对公司及控股子公司连续十二个月累计涉 及诉讼、仲裁事项进行了统计，现将有关统计情况公告如下： 一、累计新增诉讼案件的基本情况 根据《深圳证券交易所股票上市规则》有关规定，上市公司发生的诉讼、仲 裁事项应当采取连续十二个月累计计算的原则。公司及控股子公司累计涉及诉讼、 仲裁事项已达到披露标准。 截至本公告披露日，公司及控股子公司连续十二个月累计发生案件的诉讼、 仲裁金额合计为人民币 56,344.86 万元，占公司最近一期经审计净资产绝对值的 10.42%。其中，公司及控股子公司作为原告或申请人涉及的诉讼合计金额约为人 民币 50,132.35 万元；公司及控股子公司作为被告或被申请人涉及的诉讼案件合 计涉案 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2023-040 本议案以 3 票同意，0 票反对，0 票弃权的表决结果获得通过。 本议案尚需提交公司 2023 年第三次临时股东大会审议。 瑞康医药集团股份有限公司 第五届监事会第三次会议决议的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）第五届监事会第三次会议通 知于 2023 年 8 月 24 日以书面形式发出，2023 年 8 月 29 日上午在烟台市芝罘区 凤鸣路 103 号 13 号楼会议室以现场及通讯表决的方式召开。会议由张岩女士主 持，会议应出席监事 3 名，实际出席监事 3 名。会议的召开符合《中华人民共和 国公司法》和《公司章程》的规定。经与会监事审议，会议形成如下决议： 一、审议通过《关于公司及子公司担保额度预计的议案》 为满足公司及合并报表范围内子公司（以下简称"子公司"）正常的生产经营 需要，确保资金流畅通，同时加强公司及子公司对外担保的日常管理，增强公司 及子公司对外担保行为的计划性和合理性，公司为子公司提供担保、子公司互相 担 ...

证券代码：002589 证券简称：瑞康医药 公告编号：2023-035 瑞康医药集团股份有限公司 关于实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性 陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）近日接到实际控制人张仁华 女士的函告，获悉张仁华女士所持有本公司的部分股份已解除质押，具体事项如 下： 公司控股股东未来股份变动如达到《证券法》、《上市公司收购管理办法》 等规定的相关情形的，将严格遵守权益披露的相关规定，及时履行信息披露义务。 四、备查文件 股东名 称 是否为第 一大股东 及一致行 动人 解除质押 股数（万 股） 质押开始 日期 占其所持 股份比例 占公司总 股本比例 质押解除日 期 质权人 张仁华 是 4,132.00 2022 年 02 月 18 日 20.51% 2.75% 2023 年 8 月 7 日 荆州招商慧泽医药 投资合伙企业（有 限合伙） 合 计 - 4,132.00 - 20.51% 2.75% - - 一、本次解除质押的基本情况 二、股东所持股份累计被质押的情况 截至公告披露日，张仁华女士及其一致行 ...

Financial Performance - The total revenue for 2022 was ¥12,311,277,753.66, a decrease of 41.54% compared to ¥21,059,718,896.22 in 2021[25] - The net profit attributable to shareholders was -¥1,831,651,850.30, representing a decline of 1,496.31% from a profit of ¥131,178,285.52 in the previous year[25] - The net profit after deducting non-recurring gains and losses was -¥927,557,877.39, a decrease of 304.30% compared to -¥229,425,703.00 in 2021[25] - Basic earnings per share were -¥1.2424, a decline of 1,480.44% from ¥0.09 in 2021[25] - Total assets at the end of 2022 were ¥18,331,074,646.82, down 30.56% from ¥26,396,974,447.33 at the end of 2021[25] - Net assets attributable to shareholders decreased by 28.53% to ¥5,407,787,638.68 from ¥7,567,035,854.72 in 2021[25] - The company reported a significant uncertainty regarding its ability to continue as a going concern due to negative net profits in recent years[25] - The company reported a significant decline in revenue across all major regions, with Hunan province experiencing a 52.58% drop[68] - The company’s service revenue fell by 64.97% to ¥23.68 million in 2022[69] - The company’s financial assets include derivative financial assets valued at ¥67,002,767, with no impairments recorded[87] Cash Flow and Investments - Operating cash flow net amount increased by 18.09% to ¥523,073,874.41 from ¥442,952,611.75 in 2021[25] - The net cash flow from operating activities was ¥523,073,874.41, an increase of 18.09% compared to the previous year[83] - Cash and cash equivalents increased to ¥5,340,211,821.91, representing 29.13% of total assets, up from 17.35% at the beginning of the year[85] - The total investment amount for the reporting period was ¥456,286,107, representing a 13.33% increase compared to ¥402,624,352.45 in the same period last year[89] - Investment cash inflow surged by 803.57% to ¥2,531,785,150.53, while investment cash outflow increased by 124.48% to ¥1,938,827,766.52[83] Revenue Segmentation - The pharmaceutical and medical device distribution segment achieved total revenue of 8.822 billion yuan during the reporting period[44] - The IVD segment generated sales revenue of 3.246 billion yuan, focusing on providing intelligent and standardized laboratory solutions[47] - The academic services segment reported sales revenue of 75.78 million yuan, serving over 300 medical institutions[48] - The digital healthcare segment achieved sales revenue of 77.20 million yuan, leveraging AI technology for clinical medication management[50] - Revenue from the pharmaceutical equipment segment accounted for 99.19% of total revenue, declining by 41.72% year-over-year[68] - Direct sales contributed 83.57% of total revenue, with a decrease of 40.06% compared to the previous year[69] Strategic Initiatives - The company is actively expanding into innovative traditional Chinese medicine and digital healthcare sectors to establish new growth points[42] - The company plans to optimize product structure and reduce costs to improve efficiency[42] - The company is focusing on cash flow recovery and asset disposal to enhance financial stability[42] - The company aims to accelerate the innovation and commercialization of traditional Chinese medicine (TCM) products, including health foods and dietary supplements, to enhance production and sales scale[100] - The company will strengthen strategic cooperation with universities and research institutions to develop new TCM extracts and high-end products, exploring new markets and growth points[100] Management and Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation and decision-making[110] - The board of directors consists of nine members, including three independent directors, ensuring compliance with regulatory requirements[112] - The company maintains independence from its controlling shareholders in terms of business, assets, personnel, and finance, ensuring no conflicts of interest[120][122] - The company has established an independent financial department with a complete financial accounting system, ensuring financial independence and compliance[125] - The company has implemented a comprehensive investor relations management system to ensure fair treatment of all investors and timely information disclosure[179] Human Resources and Employee Engagement - The total number of employees at the end of the reporting period was 5,118, with 647 in the parent company and 3,092 in major subsidiaries[158] - The professional composition includes 2,020 sales personnel, 598 technical staff, and 242 production personnel[159] - The company has established a comprehensive salary and benefits system, along with a performance evaluation system to attract and retain talent[160] - The training program includes topics such as corporate culture, leadership, and quality management, tailored to employees' career development plans[161] - The employee stock ownership plan involved 108 employees holding a total of 30,398,300 shares, representing 2.02% of the company's total equity[164] Future Outlook and Challenges - The company plans to focus on expanding hospital distribution rights and channel sales in advantageous regions to optimize product structure and improve gross margins[99] - The company faces risks from policy changes in the healthcare sector, including price reductions and procurement policy adjustments, which may impact profitability[102] - The company aims to maintain a proactive approach to adapting to market changes and government policies to guide its operational strategies[102] - The company is actively pursuing high-end medical equipment production, traditional Chinese medicine innovation, and medical information technology (SAAS) products through self-research and external investments[104] - The company is facing management risks due to the need for higher management standards across procurement, production, R&D, sales, finance, quality, and internal control[106]

Financial Performance - The company's operating revenue for Q1 2023 was ¥2,073,027,669.16, a decrease of 49.36% compared to ¥4,093,497,042.67 in the same period last year[5] - The net profit attributable to shareholders was ¥21,159,565.23, down 50.49% from ¥42,736,596.17 year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥4,256,424.09, representing a decline of 111.08% compared to ¥38,429,500.10 in the previous year[5] - Basic earnings per share were ¥0.014, down 50.00% from ¥0.028 year-on-year[5] - Net profit for Q1 2023 was CNY 32,936,581.69, compared to CNY 146,001,703.08 in the same period last year, indicating a decrease of 77.5%[22] - The net profit for Q1 2023 was CNY 29,983,448.04, a decrease of 69.6% compared to CNY 98,579,158.25 in the same period last year[23] Cash Flow - The net cash flow from operating activities decreased by 42.36% to ¥75,590,663.40 from ¥131,152,117.17 in the same period last year[5] - Cash inflow from operating activities totaled CNY 2,428,371,185.81, a decrease of 51% from CNY 4,954,931,079.23 in the previous year[25] - The net cash flow from operating activities was CNY 75,590,663.40, down 42.5% from CNY 131,152,117.17 in Q1 2022[25] - Cash flow from investing activities showed a net inflow of CNY 247,712,308.90, compared to a net outflow of CNY 275,361,878.78 in the same period last year[26] - Cash flow from financing activities resulted in a net inflow of CNY 57,982,031.64, an increase from CNY 31,077,571.00 in Q1 2022[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥19,189,860,338.12, an increase of 4.68% from ¥18,331,074,646.82 at the end of the previous year[5] - Total current assets increased to CNY 13,947,004,834.98 from CNY 12,819,555,974.53, representing an increase of 8.8%[20] - Total non-current assets decreased to CNY 5,242,855,503.14 from CNY 5,511,518,672.29, reflecting a decline of 4.9%[20] - Total liabilities increased to CNY 13,399,986,928.74 from CNY 12,579,267,518.31, marking an increase of 6.5%[20] - Total equity increased to CNY 5,789,873,409.38 from CNY 5,751,807,128.51, showing a growth of 0.7%[20] Operational Costs - Total operating costs for Q1 2023 were CNY 2,081,916,966.47, down from CNY 3,955,744,878.12, reflecting a reduction of 47.5%[22] - Cash received from sales and services decreased by 51.65% to 224.28 million compared to the same period last year[13] - Cash paid for purchasing goods and services decreased by 42.26% to 211.71 million, reflecting a reduction in sales revenue[13] - Cash paid to employees decreased by 57.17% to 7.63 million, indicating a significant reduction in workforce-related expenses[13] - Cash paid for taxes decreased by 78.53% to 3.86 million, attributed to lower tax obligations compared to the previous year[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 100,246[15] - The top shareholder, Zhang Renrong, holds 14.39% of shares, amounting to 216.50 million shares, with a significant portion pledged[15] Miscellaneous - The company reported a significant increase in investment income of 1,837,627.59% to ¥5,328.83 due to the divestiture of a subsidiary[11] - Short-term borrowings increased by 42.77% to ¥548,213.68 from ¥383,983.47 at the beginning of the year[10] - The company’s research and development expenses decreased by 33.46% to ¥284.67 from ¥427.85 in the previous year[11] - The company’s total liabilities decreased by 62.95% in long-term borrowings to ¥2,490.00 from ¥6,720.00 due to repayment[10] - The company did not conduct an audit for the Q1 2023 report[27] - The report was released on April 29, 2023[28]

证券代码：002589 证券简称：瑞康医药 公告编号：2023-023 瑞康医药集团股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 瑞康医药集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日在巨 潮资讯网（www.cninfo.com.cn）上披露了 2022 年年度报告全文及其摘要。为进 一步加强公司与投资者的沟通交流，建立良好沟通机制，让广大投资者能深入了 解公司经营情况、未来发展战略等，公司拟举办 2022 年年度业绩说明会（以下 简称"业绩说明会"）。 登录深圳证券交易所"互动易"平台（http://irm.cninfo.com.cn），进入"云访谈" 栏目，或扫描下方二维码，参与本次业绩说明会。 二、公司出席人员 公司拟出席本次业绩说明会的人员有：公司董事长韩旭先生，董事会秘书周 云女士，财务负责人冯芸女士，独立董事于建青先生。 三、投资者问题征集 为充分尊重投资者、提升交流的针对性，现就本次业绩说明会提前向投资者 公开征集问题，广泛听取投资者的意见和建议。公司欢迎广大投资者 ...

Group 1: Company Development and Revenue Growth - In 2013, the company's basic drug distribution revenue reached 539 million CNY, a year-on-year increase of 46%. Future growth is expected with the expansion of basic drugs and new bidding processes [2] - The medical device distribution business, initiated in 2012, generated 236 million CNY in 2013, marking a significant year-on-year growth of 719.70%. The company plans to invest 135 million CNY from its private placement into this sector, anticipating further expansion through both organic growth and external acquisitions [2] - The vaccine business launched in 2013 is expected to become a new growth point for the company's revenue and profits [2] Group 2: Coverage and Market Position - The company has a strong direct coverage capability, achieving a 98% coverage rate for large hospitals in the province, 100% for tertiary hospitals, and 95% for grassroots medical institutions. This aligns with national healthcare reform policies aimed at reducing distribution links [3] - The number of upstream suppliers increased from 1,380 in 2010 to 2,147 in 2013, enhancing the company's upstream distribution rights and facilitating the expansion of downstream hospital clients [3] - The high demand for pharmaceuticals from quality hospital clients ensures secure payment and strengthens negotiations with upstream suppliers, promoting mutual resource development [3]

Group 1: Company Overview - The company has nearly full coverage in the Shandong area with a direct sales and distribution model, achieving an 86% coverage rate and serving over 2,500 hospitals [1] - The company currently covers 100% of tier-3 hospitals, 97.5% of tier-2 hospitals, and 95% of grassroots medical institutions, with over 17,000 product specifications [1] - The basic drug market is expected to reach a capacity of 60-80 billion, with rapid growth anticipated due to completed channel construction and strong partnerships with upstream enterprises [1] Group 2: Market Conditions - The basic drug market is projected to have over 800 commercial companies, with expectations of a reduction to fewer than 100 by 2015 due to industry consolidation [1] - The medical device market is fragmented, with significant potential for integration; the company’s revenue from medical devices is estimated to approach 200 million in 2013, with a market capacity of approximately 30 billion in Shandong [2] - The company’s market share in the medical device sector is currently less than 1%, indicating substantial growth potential, with projected revenue reaching 500 million in 2014 [2]